Arix Bioscience PLC (LON:ARIX) has noted the new data from portfolio company Autolus Therapeutics PLC (NASDAQ:AUTL) on AUTO3, the company’s CD19 and CD22 dual targeting CAR T anti-cancer candidate.
AUTO3 is being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma (DLBCL).
The majority of patients receiving AUTO3 in the outpatient setting did not require hospital admission, while those patients admitted were easily managed, with no patients requiring ICU care.
Dr Christian Itin, chairman and chief executive officer of Autolus, said: “This differentiated profile may widen the potential use of CAR T therapy in DLBCL.
“Based on these data, we are assessing a strategy that potentially optimizes the development path in r/r DLBCL and expect to update on next steps for AUTO3 in Q1 2021.”
Autolus released the data at the American Society of Hematology (ASH) All-Virtual Annual Meeting, held between December 5-8, 2020.
The announcement can be accessed on the Autolus website at https://www.autolus.com/investor-relations/news-and-events/press-releases .
Arix BioScience has a 6.5% ownership stake in Autolus.
